Treatment of heart failure in patients with diabetes mellitus

Abstract

The purpose of the work was to study the effect of fixed combination of meldonium dihydrate and γ-butyrobetaine dihydrate (MD+γ-BD) on clinical, hemodynamic and glucometabolic parameters, as well as indicators of oxidant-antioxidant status in patients (pts) with heart failure (HF) and type 2 diabetes mellitus (DM). The total of 62 patients with HF and DM were examined. After registration of the baseline data, baseline therapy was prescribed to all patients, 30 of them (group 1) obtained an additional fixed combination of MD+γ-BD 2 capsules three times a day for 3 months and 32 patients were included in the comparison group (group 2). After treatment in group 1, the increase of the distance walked was determined according to the 6-minute walk test by 31.2% versus 12.7% in group 2 (p <0.05). There was an increase in left ventricular (LV) ejection fraction by 4.5% in group 1 versus 1.9% in group 2 (p <0.05). Positive changes in glucometabolic parameters were observed. A decrease of the activity of lipid peroxidation processes according to the level of malondialdehyde (Δ-22.3% in patients of group 1 versus Δ-11.2% in group 2, p <0.05) and an increase in the activity of erythrocyte superoxide dismutase (respectively Δ29.5% vs. 8.1%, p <0.05) were found. Thus, an addition of a fixed combination of MD+γ-BD in the complex therapy of pts with HF and type 2 DM improves clinical symptoms in patients, has a positive effect on the structural and functional parameters of the left ventricle, glucometabolic parameters and imbalance of the oxidant-antioxidant system by increasing the activity of intracellular antioxidant enzymes